South African Dyslipidaemia Guideline Consensus Statement

References

• De Backer G, Ambrosioni E, Borch-Johnson K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601–1610.
   PubMed Web of Science ®Google Scholar
• South African Medical Association and Lipid and Atherosclerosis Society of Southern Africa Working Group. Diagnosis, management and prevention of the common dyslipidaemias in South Africa—Clinical Guideline, 2000. S Afr Med J 2000; 90: 164–178.
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al, for the Task Force for the management of dyslipidaemias of the European Society for Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769–1818.
   PubMed Web of Science ®Google Scholar
• Steyn K. Heart disease in South Africa. Media data document. Heart and Stroke Foundation South Africa, July 2007.
   Google Scholar
• Steyn K, Sliwa K, Hawken S, et al. Risk factors associated with myocardial infarction in Africa. The INTERHEART Africa Study. Circulation 2005; 112: 3554–3561.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937–952.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health, National Heart, Lung & Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. NIH Publication No. 01–3670, May 2001. Bethesda, Md, 2001.
   Google Scholar
• Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: A guideline from the American Heart Association. Circulation 2011; 123: 1243–1262.
   PubMed Web of Science ®Google Scholar
• D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743–753.
   PubMed Web of Science ®Google Scholar
• Batki AD, Nayyar P, Thomason HL. Buyer's guide: Point-of-care testing for cholesterol measurement. NHS Purchasing and Supply Agency. Center for Evidence-based Purchasing. CEP 09020; September 2009. http://www.healthcheck.nhs.uk/Library/pointofcare_testing_for_cholesterol_measurement.pdf (accessed 26 October 2011).
   Google Scholar
• Sacks F Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360(9): 859–873.
   PubMed Web of Science ®Google Scholar
• Violil F, Pignatelli P, Basili S. et al. Nutrition, supplements and vitamins in platelet functions and bleeding. Circulation 2010; 121: 1033–1044.
   PubMed Web of Science ®Google Scholar
• Mursu J, Robien K, Harnack LJ, et al. Dietary supplements and mortality rate in older women. The IOWA Women's Health Study. Arch Intern Med 2011; 171(18): 1625–1633.
   PubMed Web of Science ®Google Scholar
• Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. A systematic review. J Am Coll Cardiol 2007; 49(23): 2231–2237.
   PubMed Web of Science ®Google Scholar
• Schaars CF, Stalenhoef AFH. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008; 19: 553–557.
   PubMed Web of Science ®Google Scholar
• Egan A, Coleman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med 2011; 365(4): 285–287.
   PubMed Web of Science ®Google Scholar
• Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010; 95(5): 2015–2022.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 2011; 305(24): 2556–2564.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375(9716): 735–742.
   PubMed Web of Science ®Google Scholar
• Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diab Care 2009; 32: 1924–1929.
   PubMed Web of Science ®Google Scholar
• Weng T-C, Kao Yang Y-H, Lin S-J, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010; 35: 139–151.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo controlled trial. Lancet 2011; 377: 2181–2181.
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–1645.
   PubMed Web of Science ®Google Scholar